ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Guggenheim in a research note issued to investors on Friday,Benzinga reports. They presently have a $86.00 price target on the specialty pharmaceutical company's stock. Guggenheim's target price indicates a potential upside of 23.65% from the company's previous close.
A number of other brokerages have also recently weighed in on ANIP. HC Wainwright reiterated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, April 8th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.
Read Our Latest Stock Report on ANIP
ANI Pharmaceuticals Stock Performance
Shares of ANI Pharmaceuticals stock traded up $0.83 during trading hours on Friday, reaching $69.55. The company's stock had a trading volume of 191,896 shares, compared to its average volume of 268,605. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.00. The company's 50 day simple moving average is $62.52 and its 200 day simple moving average is $59.15. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a market cap of $1.51 billion, a P/E ratio of -126.45 and a beta of 0.49.
Insider Activity at ANI Pharmaceuticals
In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the sale, the vice president now owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. This represents a 0.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,200 shares of company stock valued at $197,792. Corporate insiders own 12.70% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. GAMMA Investing LLC raised its holdings in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock valued at $2,648,000 after purchasing an additional 13,948 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $1,128,000. Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals in the fourth quarter worth about $200,000. Finally, ProShare Advisors LLC boosted its stake in ANI Pharmaceuticals by 29.0% during the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock valued at $361,000 after purchasing an additional 1,469 shares during the period. Institutional investors own 76.05% of the company's stock.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
